U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07233642) titled 'Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE' on Sept. 28.
Brief Summary: This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
BIOLOGICAL: CD19 CAR-T cells
Three dose groups (1.5x10^5/kg, 5x10^5/kg, 10x10^5/kg) were set up, starting from the low dose group climbing to explore the safe and effective dose.
Recruitment Status: RECRUITING
Sponsor: The Children's Hospi...